Johns Hopkins To Begin Blood Plasma Trials For Treatment Of COVID-19
Johns Hopkins To Begin Blood Plasma Trials For Treatment Of COVID-19

Johns Hopkins University will begin two clinical trials of convalescent blood plasma to treat COVID-19 next week.

Convalescent blood plasma is plasma derived from the blood of COVID-19 survivors.

According to UPI, researchers said the trials will focus on healthcare workers and nursing home residents.

Researchers theorize that the blood from recovered patients contains antibodies that may fight the virus.

Doctors hope that treatment will cut down on the need to hospitalize patients.